药理学更新:苏泽特里金:一种用于急性疼痛管理的新型NaV1.8道抑制剂
Supriya Peshin1, Claudia Villa Celi2, Saima Rashid3
1Department of Internal Medicine, Norton Community Hospital, Norton, VA, USA.
The American journal of hospice & palliative care
|July 2, 2025
概括
苏丁,一种新的NaV1.8抑制剂,通过向疼痛信号而有效地控制急性疼痛,没有阿片类风险. 临床试验显示效果与可相似,在疼痛管理方面具有有利的安全性.
科学领域:
- 药理学和疼痛管理
- 神经科学是一个神经科学.
- 药物开发 药物开发
背景情况:
- 基于阿片类药物的止痛药具有成,镇静和呼吸抑制的风险.
- 传统的疼痛管理通常涉及非类固醇抗炎药物 (NSAID) 或阿片类药物.
- 需要有效的急性疼痛治疗,并改善安全性.
研究的目的:
- 审查suzetrigine的药理学,作用机制和临床疗效.
- 评估suzetrigine作为阿片类药物的替代品在急性疼痛管理中的潜力.
- 评估suzetrigine的安全性和潜在的临床应用.
主要方法:
- 关于suzetrigine和NaV1.8抑制剂的临床前和临床研究的文献综述.
- 检查suzetrigine对NaV1.8通道的选择性抑制.
- 对手术后疼痛减轻的第二期临床试验数据的分析.
主要成果:
- 苏泽丁可以选择性地抑制NaV1.8通道,减少疼痛信号传输.
- 临床前研究表明,在动物模型中,可感知行为减少.
- 第二阶段试验表明,与可/乙氨基相比,可显著减少疼痛,耐受性良好.
结论:
- 苏二烯为急性疼痛管理提供了一个有前途的替代品,具有有利的安全性.
- 它的选择性机制可能会降低与阿片类药物相关的风险,有助于阿片类药物危机.
- 需要进一步的研究来确定长期疗效和在慢性疼痛中使用.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
459
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
459
Antiepileptic Drugs: Potassium Channel Activators
286
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
286
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
Antiepileptic Drugs: Sodium Channel Blockers
927
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
927
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
265
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
265
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K


